These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

615 related articles for article (PubMed ID: 24469825)

  • 21. Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration.
    Eggers C; Hertogs K; Stürenburg HJ; van Lunzen J; Stellbrink HJ
    AIDS; 2003 Sep; 17(13):1897-906. PubMed ID: 12960822
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reduction of the HIV-1-infected T-cell reservoir by immune activation treatment is dose-dependent and restricted by the potency of antiretroviral drugs.
    Fraser C; Ferguson NM; Ghani AC; Prins JM; Lange JM; Goudsmit J; Anderson RM; de Wolf F
    AIDS; 2000 Apr; 14(6):659-69. PubMed ID: 10807189
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Virus burden in lymph nodes and blood of subjects with primary human immunodeficiency virus type 1 infection on bitherapy.
    Perrin L; Yerly S; Marchal F; Schockmel GA; Hirschel B; Fox CH; Pantaleo G
    J Infect Dis; 1998 Jun; 177(6):1497-501. PubMed ID: 9607825
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of mycophenolate mofetil on immune response and plasma and lymphatic tissue viral load during and after interruption of highly active antiretroviral therapy for patients with chronic HIV infection: a randomized pilot study.
    García F; Plana M; Arnedo M; Brunet M; Castro P; Gil C; Vidal E; Millán O; López A; Martorell J; Fumero E; Miró JM; Alcamí J; Pumarola T; Gallart T; Gatell JM
    J Acquir Immune Defic Syndr; 2004 Jul; 36(3):823-30. PubMed ID: 15213566
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial).
    Stellbrink HJ; van Lunzen J; Westby M; O'Sullivan E; Schneider C; Adam A; Weitner L; Kuhlmann B; Hoffmann C; Fenske S; Aries PS; Degen O; Eggers C; Petersen H; Haag F; Horst HA; Dalhoff K; Möcklinghoff C; Cammack N; Tenner-Racz K; Racz P
    AIDS; 2002 Jul; 16(11):1479-87. PubMed ID: 12131185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Cell and tissue reservoirs of HIV-1: dynamics during infection].
    Trémeaux P; Rouzioux C; Avettand-Fènoël V
    Virologie (Montrouge); 2019 Aug; 23(4):211-228. PubMed ID: 31414659
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune activation, HIV persistence, and the cure.
    Douek DC
    Top Antivir Med; 2013; 21(4):128-32. PubMed ID: 24225078
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimization of lipid-indinavir complexes for localization in lymphoid tissues of HIV-infected macaques.
    Kinman L; Bui T; Larsen K; Tsai CC; Anderson D; Morton WR; Hu SL; Ho RJ
    J Acquir Immune Defic Syndr; 2006 Jun; 42(2):155-61. PubMed ID: 16760797
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment-induced decline of human immunodeficiency virus-1 p24 and HIV-1 RNA in lymphoid tissue of patients with early human immunodeficiency virus-1 infection.
    Kuster H; Opravil M; Ott P; Schlaepfer E; Fischer M; Günthard HF; Lüthy R; Weber R; Cone RW
    Am J Pathol; 2000 Jun; 156(6):1973-86. PubMed ID: 10854220
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [AIDS: new developments. VI. HIV reservoirs during intensive antiretroviral treatment].
    Notermans DW; Danner SA; de Wolf F; Lange JM
    Ned Tijdschr Geneeskd; 1998 Aug; 142(34):1909-12. PubMed ID: 9856176
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The immunosuppressive role of IL-32 in lymphatic tissue during HIV-1 infection.
    Smith AJ; Toledo CM; Wietgrefe SW; Duan L; Schacker TW; Reilly CS; Haase AT
    J Immunol; 2011 Jun; 186(11):6576-84. PubMed ID: 21525393
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Toxicity, biological activity, and pharmacokinetics of TXU (anti-CD7)-pokeweed antiviral protein in chimpanzees and adult patients infected with human immunodeficiency virus.
    Uckun FM; Bellomy K; O'Neill K; Messinger Y; Johnson T; Chen CL
    J Pharmacol Exp Ther; 1999 Dec; 291(3):1301-7. PubMed ID: 10565855
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantitative image analysis of HIV-1 infection in lymphoid tissue.
    Haase AT; Henry K; Zupancic M; Sedgewick G; Faust RA; Melroe H; Cavert W; Gebhard K; Staskus K; Zhang ZQ; Dailey PJ; Balfour HH; Erice A; Perelson AS
    Science; 1996 Nov; 274(5289):985-9. PubMed ID: 8875941
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HIV-1 viral replication below 50 copies/ml in patients on antiretroviral therapy is not associated with CD8+ T-cell activation.
    Steel A; Cox AE; Shamji MH; John L; Nelson M; Henderson DC; Gotch FM; Gazzard BG; Kelleher P
    Antivir Ther; 2007; 12(6):971-5. PubMed ID: 17926652
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lipid-drug association enhanced HIV-1 protease inhibitor indinavir localization in lymphoid tissues and viral load reduction: a proof of concept study in HIV-2287-infected macaques.
    Kinman L; Brodie SJ; Tsai CC; Bui T; Larsen K; Schmidt A; Anderson D; Morton WR; Hu SL; Ho RJ
    J Acquir Immune Defic Syndr; 2003 Dec; 34(4):387-97. PubMed ID: 14615656
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Two-year clinical and immune outcomes in human immunodeficiency virus-infected children who reconstitute CD4 T cells without control of viral replication after combination antiretroviral therapy.
    Ghaffari G; Passalacqua DJ; Caicedo JL; Goodenow MM; Sleasman JW
    Pediatrics; 2004 Nov; 114(5):e604-11. PubMed ID: 15492356
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Decay of cell-associated HIV-1 DNA correlates with residual replication in patients treated during acute HIV-1 infection.
    Yerly S; Perneger TV; Vora S; Hirschel B; Perrin L
    AIDS; 2000 Dec; 14(18):2805-12. PubMed ID: 11153661
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults.
    Jacobson JM; Kuritzkes DR; Godofsky E; DeJesus E; Larson JA; Weinheimer SP; Lewis ST
    Antimicrob Agents Chemother; 2009 Feb; 53(2):450-7. PubMed ID: 19015347
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs.
    Katlama C; Deeks SG; Autran B; Martinez-Picado J; van Lunzen J; Rouzioux C; Miller M; Vella S; Schmitz JE; Ahlers J; Richman DD; Sekaly RP
    Lancet; 2013 Jun; 381(9883):2109-17. PubMed ID: 23541541
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pilot study of a combination of highly active antiretroviral therapy and cytokines to induce HIV-1 remission.
    Lafeuillade A; Poggi C; Chadapaud S; Hittinger G; Chouraqui M; Pisapia M; Delbeke E
    J Acquir Immune Defic Syndr; 2001 Jan; 26(1):44-55. PubMed ID: 11176268
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.